Introduction: Eclampsia is an extremely severe form of preeclampsia characterized by sudden onset of generalized tonic-clonic seizures responsible for 17–30% maternal mortality and 22% perinatal mortality. Since then, MgSO4 has been proven to more than halve the risk of occurrence of eclampsia in women with preeclampsia and of recurrence in women with eclampsia. Material and Methods: This is a Prospective study conducted in the Department of Obstetrics and Gynaecology at Shadan Institute of Medical Sciences, Teaching Hospital & Research Centre, Hyderabad over a period of 1 year. Eclamptic patients who got admitted in department of obstetrics and gynecology. Standard principles of management of eclampsia will be followed. Patients are divided into two groups as cases & control alternatively. Groups are chosen based on inclusion & exclusion criteria. Group I Control will follow Pritchard standard regimen. Group II Cases will receive low dose magnesium sulphate regimen. Result: Among low dose and standard regime groups about 11.4% & 17.1% each had previous history of PIH. Among low dose group, 15% were intra uterine deaths, 20% needed NICU admissions, 10% were early neonatal deaths and none were perinatal deaths. Among standard regime group, 20% were intra uterine death, 30% were NICU admissions, 25% were early neonatal deaths &10% were perinatal deaths. The average birth weight among low dose and standard group was 2.18kgs and 2.02kgs respectively. The mean APGAR score at 5 minutes was 7.21 among low dose and 6.4 among standard regimen. There is no major correlation in both groups with respect to fetal outcome. Conclusion: The occurrence of eclampsia in two groups was more common in the age range of 20 to 26 years among the primigravida and with previous history of PIH. There is no major difference in the outcome of maternal and fetal in both groups. Nonetheless the magnesium levels among low dose group are significantly lower in comparison with standard regimen group. In cases and controls the magnesium levels are maintained in normal therapeutic range. Low dose regimen is better alternative to control seizures in eclamptic patients.